Drugs / LY4065967
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07607483 | Jun → Jul 2026 overdue | — | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07039045 | Jun → Aug 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06594159 | Oct 2024 → Mar 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07641504 | Jul 2026 → Apr 2027 expected | chronic pain syndrome | Eli Lilly and Company | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07641517 | Jul 2026 → Apr 2027 expected | chronic pain syndrome, osteoarthritis, knee | Eli Lilly and Company | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07285018 | Feb 2026 → Jul 2027 expected | diabetic polyneuropathy | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4065967 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06594159 ↗ |
| Route | Oral | “A single dose of LY4065967 administered orally” NCT06594159 ↗ |